BioCryst Pharmaceuticals, Inc. (BCRX)
7.09
-0.31
(-4.19%)
USD |
NASDAQ |
Jan 12, 16:00
7.10
+0.01
(+0.14%)
After-Hours: 20:00
BioCryst Pharmaceuticals Research and Development Expense (Quarterly): 44.27M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Astria Therapeutics, Inc. | 24.15M |
| Hologic, Inc. | 65.10M |
| Johnson & Johnson | 3.693B |
| Viatris, Inc. | 244.80M |
| KalVista Pharmaceuticals, Inc. | 11.99M |